Starting July 1, 2026, eligible Medicare patients with obesity can access Wegovy (semaglutide) for a $50 monthly copay through the new Medicare GLP-1 Bridge program. This initiative, in partnership with Novo Nordisk, covers all Wegovy doses and forms nationwide until the end of 2027, expanding access to FDA-approved obesity treatments. Meanwhile, Amazon Pharmacy is enhancing access to the oral Ozempic pill with same-day delivery and in-office pickup options, making diabetes treatment more convenient for insured customers.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
